Alivus Life Sciences Limited — Investor Meet, 30-01-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Alivus Life Sciences achieved its highest-ever Q3 revenue of Rs. 673 Cr (+14.4% QoQ) and EBITDA margin of 36.4% (+510 bps YoY). Performance was strong across API generics in regulated markets and a robust CDMO recovery, with revenue growing 100% QoQ. The non-GPL business grew 16.1% for the nine-month period. Management projects high single-digit revenue growth for FY26 and healthy 30-32% margins, driven by new product launches, favorable product mix, and operational efficiencies. Capacity expansions are progressing, with Solapur operations starting in July. The company maintains a net debt-free status with strong cash generation.